Jacob Eric Lemieux

Jacob Eric Lemieux

Auto-generated profile, based on publicly available information

Jacob Eric Lemieux

Massachusetts General Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in Science
Verified
Journal Article
Open access
FOFritz Obermeyer
Fritz Obermeyer
MJMartin Jankowiak
Martin Jankowiak
NBNikolaos Barkas
Nikolaos Barkas
SSStephen Schaffner
Stephen Schaffner
JPJesse D. Pyle
Jesse D. Pyle
JLJacob E. Lemieux
Jacob E. Lemieux
Repeated emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased fitness underscores the value of rapid detection and characterization of new lineages. We have developed PyR 0 , a hierarchical Bayesian multinomial logistic regression model that infers relative prevalence of all viral lineages across geographic regions, detects lineages increasing in prevalence, and identifies mutations relevant to fitness. Applying PyR 0 to all publicly available SARS-CoV-2 genomes, we identify numerous substitutions that increase fitness, including previously identified spike mutations and many nonspike mutations within the nucleocapsid and nonstructural proteins. PyR 0 forecasts growth of new lineages from their mutational profile, ranks the fitness of lineages as new sequences become available, and prioritizes mutations of biological and public health concern for functional characterization.

5 February 2021 in Science
Verified
Journal Article
Open access
PDF file
JLJacob E. Lemieux
Jacob E. Lemieux
KSKatherine Siddle
Katherine Siddle
BSBennett M. Shaw
Bennett M. Shaw
CLChristine Loreth
Christine Loreth
SSStephen Schaffner
Stephen Schaffner
BMBronwyn L. MacInnis
Bronwyn L. MacInnis
Phylogenetics of superspreading: One important characteristic of coronavirus epidemiology is the occurrence of superspreading events. These are marked by a disproportionate number of cases originating from often-times asymptomatic individuals. Using a rich sequence dataset from the early stages of the Boston outbreak, Lemieuxet al.identified superspreading events in specific settings and analyzed them phylogenetically (see the Perspective by Alizon). Using ancestral trait inference, the authors identified several importation events, further investigated the context and contribution of particular superspreading events to the establishment of local and wider SARS-CoV-2 transmission, and used viral phylogenies to describe sustained transmission.Science, this issue p.eabe3261; see also p.574

24 January 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
YLYijia Li
Yijia Li
MCManish Chandra Choudhary
Manish Chandra Choudhary
JRJames Regan
James Regan
JBJulie Boucau
Julie Boucau
ANAnusha Nathan
Anusha Nathan
JLJonathan Z. Li
Jonathan Z. Li
Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the immune defects that predispose an individual to persistent coronavirus disease 2019 (COVID-19) remain incompletely understood. In this study, we performed detailed viro-immunologic analyses of a prospective cohort of participants with COVID-19. The median times to nasal viral RNA and culture clearance in individuals with severe immunosuppression due to hematologic malignancy or transplant (S-HT) were 72 and 40 days, respectively, both of which were significantly longer than clearance rates in individuals with severe immunosuppression due to autoimmunity or B cell deficiency (S-A), individuals with nonsevere immunodeficiency, and nonimmunocompromised groups ( P < 0.01). Participants who were severely immunocompromised had greater SARS-CoV-2 evolution and a higher risk of developing resistance against therapeutic monoclonal antibodies. Both S-HT and S-A participants had diminished SARS-CoV-2–specific humoral responses, whereas only the S-HT group had reduced T cell–mediated responses. This highlights the varied risk of persistent COVID-19 across distinct immunosuppressive conditions and suggests that suppression of both B and T cell responses results in the highest contributing risk of persistent infection.

1 December 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
GEGregory E. Edelstein
Gregory E. Edelstein
JBJulie Boucau
Julie Boucau
RURockib Uddin
Rockib Uddin
CMCaitlin Marino
Caitlin Marino
MLMay Y. Liew
May Y. Liew
MSMark J. Siedner
Mark J. Siedner
Data are conflicting regarding an association between treatment of acute COVID-19 with nirmatrelvir-ritonavir (N-R) and virologic rebound (VR). To compare the frequency of VR in patients with and without N-R treatment for acute COVID-19. Observational cohort study. Multicenter health care system in Boston, Massachusetts. Ambulatory adults with acute COVID-19 with and without use of N-R. Receipt of 5 days of N-R treatment versus no COVID-19 therapy. The primary outcome was VR, defined as either a positive SARS-CoV-2 viral culture result after a prior negative result or 2 consecutive viral loads above 4.0 log10 copies/mL that were also at least 1.0 log10 copies/mL higher than a prior viral load below 4.0 log10 copies/mL. Compared with untreated persons (n = 55), those taking N-R (n = 72) were older, received more COVID-19 vaccinations, and more commonly had immunosuppression. Fifteen participants (20.8%) taking N-R had VR versus 1 (1.8%) who was untreated (absolute difference, 19.0 percentage points [95% CI, 9.0 to 29.0 percentage points]; P = 0.001). All persons with VR had a positive viral culture result after a prior negative result. In multivariable models, only N-R use was associated with VR (adjusted odds ratio, 10.02 [CI, 1.13 to 88.74]; P = 0.038). Virologic rebound was more common among those who started therapy within 2 days of symptom onset (26.3%) than among those who started 2 or more days after symptom onset (0%) (P = 0.030). Among participants receiving N-R, those who had VR had prolonged shedding of replication-competent virus compared with those who did not have VR (median, 14 vs. 3 days). Eight of 16 participants (50% [CI, 25% to 75%]) with VR also reported symptom rebound; 2 were completely asymptomatic. No post-VR resistance mutations were detected. Observational study design with differences between the treated and untreated groups; positive viral culture result was used as a surrogate marker for risk for ongoing viral transmission. Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus. National Institutes of Health.

25 January 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
MSMark J. Siedner
Mark J. Siedner
JBJulie Boucau
Julie Boucau
RGRebecca F. Gilbert
Rebecca F. Gilbert
RURockib Uddin
Rockib Uddin
JLJonathan Luu
Jonathan Luu
JLJonathan Z. Li
Jonathan Z. Li
Isolation guidelines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are largely derived from data collected prior to the emergence of the delta variant. We followed a cohort of ambulatory patients with postvaccination breakthrough SARS-CoV-2 infections with longitudinal collection of nasal swabs for SARS-CoV-2 viral load quantification, whole-genome sequencing, and viral culture. All delta variant infections in our cohort were symptomatic, compared with 64% of non-delta variant infections. Symptomatic delta variant breakthrough infections were characterized by higher initial viral load, longer duration of virologic shedding by PCR, greater likelihood of replication-competent virus at early stages of infection, and longer duration of culturable virus compared with non-delta variants. The duration of time since vaccination was also correlated with both duration of PCR positivity and duration of detection of replication-competent virus. Nonetheless, no individuals with symptomatic delta variant infections had replication-competent virus by day 10 after symptom onset or 24 hours after resolution of symptoms. These data support US CDC isolation guidelines as of November 2021, which recommend isolation for 10 days or until symptom resolution and reinforce the importance of prompt testing and isolation among symptomatic individuals with delta breakthrough infections. Additional data are needed to evaluate these relationships among asymptomatic and more severe delta variant breakthrough infections.

31 August 2023 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JLJacob E. Lemieux
Jacob E. Lemieux
WHWeihua Huang
Weihua Huang
NHNathan Hill
Nathan Hill
TCTjasa Cerar
Tjasa Cerar
LFLisa Freimark
Lisa Freimark
KSKlemen Strle
Klemen Strle
Lyme disease is the most common vector-borne disease in North America and Europe. The clinical manifestations of Lyme disease vary based on the genospecies of the infectingBorrelia burgdorferispirochete, but the microbial genetic elements underlying these associations are not known. Here, we report the whole genome sequence (WGS) and analysis of 299B.burgdorferi(Bb) isolates derived from patients in the Eastern and Midwestern US and Central Europe. We develop a WGS-based classification ofBbisolates, confirm and extend the findings of previous single- and multi-locus typing systems, define the plasmid profiles of human-infectiousBbisolates, annotate the core and strain-variable surface lipoproteome, and identify loci associated with disseminated infection. A core genome consisting of ~900 open reading frames and a core set of plasmids consisting of lp17, lp25, lp36, lp28-3, lp28-4, lp54, and cp26 are found in nearly all isolates. Strain-variable (accessory) plasmids and genes correlate strongly with phylogeny. Using genetic association study methods, we identify an accessory genome signature associated with dissemination in humans and define the individual plasmids and genes that make up this signature. Strains within the RST1/WGS A subgroup, particularly a subset marked by the OspC type A genotype, have increased rates of dissemination in humans. OspC type A strains possess a unique set of strongly linked genetic elements including the presence of lp56 and lp28-1 plasmids and a cluster of genes that may contribute to their enhanced virulence compared to other genotypes. These features of OspC type A strains reflect a broader paradigm acrossBbisolates, in which near-clonal genotypes are defined by strain-specific clusters of linked genetic elements, particularly those encoding surface-exposed lipoproteins. These clusters of genes are maintained by strain-specific patterns of plasmid occupancy and are associated with the probability of invasive infection.